v3.25.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenue:    
Total revenue $ 14
Operating expenses:    
Research and development 6 238
General and administrative 2,957 2,882
Impairment of long term assets 253
Depreciation and amortization 21 78
Total operating expenses 2,984 3,451
Loss from operations (2,984) (3,437)
Other income (expense)    
Interest expense, net (3)
Gain on settlement and extinguishment of accounts payable 199
Other income (expense), net (15) 25
Total other income (expense), net 184 22
Loss before income taxes (2,800) (3,415)
Income taxes (benefit)
Net loss (2,800) (3,415)
Non-controlling interest (12) 13
Net loss attributable to BioSig Technologies, Inc. (2,812) (3,402)
Preferred stock dividend (2) (2)
Preferred stock deemed dividend (133)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS $ (2,814) $ (3,537)
Net loss per common share, basic $ (0.14) $ (0.36)
Net loss per common share, diluted $ (0.14) $ (0.36)
Weighted average number of common shares outstanding, basic 20,787,808 9,856,261
Weighted average number of common shares outstanding, diluted 20,787,808 9,856,261
Service [Member]    
Revenue:    
Total revenue $ 14

Source